ArticleTherapeutic advances in drug safety2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients.
Stefania Crucitta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.